Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.52 |
| ▸ | MMP13 | P45452 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SPR | P35270 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31214531 | 0.88 | HPGD (0.58) | HPGDMMP13CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31214422 | 0.88 | MAPT (0.48) | HPGDMMP13CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31214533 | 0.87 | MAPT (0.55) | HPGDMMP13CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31214496 | 0.86 | HPGD (0.55) | HPGDMMP13CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31150961 | 0.86 | HPGD (0.58) | HPGDMMP13CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31214443 | 0.86 | HPGD (0.55) | HPGDMMP13CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31214495 | 0.86 | HPGD (0.55) | HPGDMMP13CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31214560 | 0.85 | HPGD (0.57) | HPGDMMP13CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31214457 | 0.85 | HPGD (0.52) | HPGDMMP13CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31214484 | 0.84 | HPGD (0.53) | HPGDMMP13CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688754-A1 | KCC2 POTENTIATORS AND USES THEREOF | Axonis Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260028351-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. | 2026-01-29 | — | — | US | disclosed |
| WO-2024211744-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028351-A1 | KCC2 POTENTIATORS AND USES THEREOF | GRIN2C, HCN1, KCNC1 | HPGD 2883/4885MMP13 3831/4885CYP1A2 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.